Nevro (NYSE:NVRO) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO) in a report released on Tuesday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

Other research analysts have also recently issued reports about the company. Jefferies Financial Group raised Nevro from an “underperform” rating to a “hold” rating and lifted their price target for the company from $4.50 to $5.85 in a report on Monday, February 10th. Truist Financial dropped their target price on shares of Nevro from $7.00 to $4.70 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Piper Sandler raised shares of Nevro from a “neutral” rating to an “overweight” rating and decreased their price target for the company from $6.00 to $5.85 in a research note on Friday, February 7th. Robert W. Baird boosted their price objective on shares of Nevro from $5.00 to $6.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 12th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $7.00 price objective on shares of Nevro in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $6.43.

Nevro Trading Down 0.1 %

Nevro stock opened at $5.72 on Tuesday. Nevro has a 52 week low of $3.16 and a 52 week high of $17.53. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.76 and a current ratio of 5.02. The firm has a market capitalization of $214.14 million, a PE ratio of -3.02 and a beta of 0.91. The business’s 50-day simple moving average is $4.53 and its 200-day simple moving average is $4.96.

Institutional Investors Weigh In On Nevro

Several large investors have recently added to or reduced their stakes in NVRO. Amundi acquired a new position in Nevro during the fourth quarter worth $30,000. Oxford Asset Management LLP acquired a new stake in shares of Nevro in the 4th quarter worth about $39,000. Corton Capital Inc. bought a new position in Nevro in the 4th quarter valued at about $43,000. Headlands Technologies LLC acquired a new position in Nevro during the 4th quarter valued at about $45,000. Finally, Ieq Capital LLC bought a new stake in Nevro during the 4th quarter worth approximately $46,000. Institutional investors and hedge funds own 95.52% of the company’s stock.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.